Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

Beta Bionics faces a securities class action lawsuit alleging the company failed to disclose that its iLet insulin pump had a malfunctioning automated dosing algorithm causing dangerously high insulin delivery and hypoglycemic events. The company allegedly received thousands of complaints it failed to report to the FDA, and an FDA Form 483 identified over 18,000 unreported complaints. Investors with losses exceeding $100,000 have until November 3, 2026 to file lead plaintiff applications.